A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
Clinical trial NCT02266927 · COMPLETED
Trial details
- NCT number
- NCT02266927
- Sponsor
- Optinose US Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2015-03-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.